MBX
vs
S
S&P TSX Composite Index (Canada)
MBX
Over the past 12 months, MBX has underperformed S&P TSX Composite Index (Canada), delivering a return of -46% compared to the S&P TSX Composite Index (Canada)'s +28% growth.
Stocks Performance
MBX vs S&P TSX Composite Index (Canada)
Performance Gap
MBX vs S&P TSX Composite Index (Canada)
Performance By Year
MBX vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Microbix Biosystems Inc
Glance View
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm manufactures a range of biological materials for the diagnostics industry, notably antigens (Antigen business) used in immunoassays and its quality assessment and proficiency testing controls (QAPs business). The firm operates in two segments: the development, manufacturing, and sales of antigens as materials for the medical diagnostic industry or as quality assessment products (as finished products) and viral transport medium (VTM) and the development and commercialization of products or technologies such as Kinlytic and . The Kinlyti urokinase, which is a biologic thrombolytic drug used to treat blood clots. The firm's catalogue of catalogue covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted and insect-borne diseases. Its QAPs are available in over 30 countries.
